Literature DB >> 19204674

Avastin-Tarceva combination fails in lung cancer.

Dan Jones.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19204674     DOI: 10.1038/nbt0209-108

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

Review 1.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Authors:  John M L Ebos; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

2.  Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?

Authors:  Grzegorz Korpanty; Elizabeth Smyth; Desmond N Carney
Journal:  J Thorac Dis       Date:  2011-03       Impact factor: 2.895

Review 3.  Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.

Authors:  Annamaria Rapisarda; Giovanni Melillo
Journal:  Nat Rev Clin Oncol       Date:  2012-04-24       Impact factor: 66.675

4.  Pre-clinical drug prioritization via prognosis-guided genetic interaction networks.

Authors:  Jianghui Xiong; Juan Liu; Simon Rayner; Ze Tian; Yinghui Li; Shanguang Chen
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

5.  Rhamnolipid-coated W/O/W double emulsion nanoparticles for efficient delivery of doxorubicin/erlotinib and combination chemotherapy.

Authors:  Yeeun Lee; Donghyun Lee; Eunyoung Park; Seok-Young Jang; Seo Young Cheon; Seongryeong Han; Heebeom Koo
Journal:  J Nanobiotechnology       Date:  2021-12-07       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.